Paperonium

Breast cancer · Clin Cancer Res · 2024

Summary: “significantly” longer survival. Its own test: about 1 in 18, short of its 1-in-20 rule.

1 in 100every time1 in 20the usual barjust shortrarer than1 in 20The summary: “significant”about1 in 18Its own test: fails the rule
1 in 100every time1 in 20the usual barjust shortrarer than1 in 20The summary:“significant”about1 in 18Its own test:fails the rule

How often chance alone gives this survival gap if tumor type doesn’t matter

The paper says

In patients with one kind of breast cancer, a test of which genes are active in each tumor sorted most into two types, named “basal” (64 patients) and “HER2-enriched” (12). The summary’s only survival result says the 12 lived “significantly” longer than the 64.

Its own data show

Its only test of this gives p = 0.055, about 1 time in 18. That is more often than 1 in 20, so it fails the paper’s own rule for “significant”. Elsewhere it calls another result, p = 0.056, “nonsignificant”. We reran the test on the patient-by-patient data published with the paper: 0.055 again.

A p-value is how often chance alone would produce a gap this big if tumor type made no difference. The paper’s rule: “significant” means rarer than 1 time in 20. With only 12 patients, the longer survival (half had died by 1,258 days, versus 510 for basal) is a hint, not proof. Its main findings don’t rest on it.

“The summary” means the paper’s abstract: the short summary printed at its top, which is the part most readers see.

Read the paper →Full technical write-up →

Integrative Multiomic Profiling of Triple-Negative Breast Cancer for Identifying Suitable Therapies · Clin Cancer Res (2024) · doi:10.1158/1078-0432.CCR-23-1242